12:28 PM
 | 
Jun 15, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Eureka reports Phase I response data for anti-CD19 T cell therapy in lymphoma

Eureka Therapeutics Inc. (Emeryville, Calif.) reported preliminary data from 17 evaluable patients with CD19-positive, relapsed and refractory B cell lymphoma in a Phase I trial showing that IV ET190L1-ARTEMIS led to seven complete metabolic responses and three partial...

Read the full 168 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >